These findings suggest that PCSK9 inhibitors not only influence the degradation of LDLR but may also regulate lipid metabolism and inflammatory responses through various pathways, further impacting the progression of cardiovascular diseases. This evidence concerns the gene PCSK9 and cardiovascular disorder.